Your SlideShare is downloading. ×
  • Like
Diabetes Therapeutics Market in India to 2018 Available on Researchmoz.us
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×

Now you can save presentations on your phone or tablet

Available for both IPhone and Android

Text the download link to your phone

Standard text messaging rates apply

Diabetes Therapeutics Market in India to 2018 Available on Researchmoz.us

  • 120 views
Published

GBI Research, the leading business intelligence provider, has released its latest research Diabetes Therapeutics Market in India to 2018 Rapid Uptake of DPP-IV Inhibitors, GLP-1 Agonists and Expanding …

GBI Research, the leading business intelligence provider, has released its latest research Diabetes Therapeutics Market in India to 2018 Rapid Uptake of DPP-IV Inhibitors, GLP-1 Agonists and Expanding Insulin Segment to Drive Growth, which provides insights into the India anti-diabetes market until 2018. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Researchs team of industry experts. Insights into the diabetes epidemiology, cost of therapy, research and development pipeline and the promising molecules which are anticipated to be launched by 2018 are discussed in the report.

Published in Health & Medicine
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
120
On SlideShare
0
From Embeds
0
Number of Embeds
0

Actions

Shares
Downloads
4
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. Diabetes Therapeutics Market in India to 2018 - Rapid Uptake of DPP-IV Inhibitors, GLP-1 Agonists andExpanding Insulin Segment to Drive Growth Diabetes Therapeutics Market in India to 2018 Rapid Uptake of DPP-IV Inhibitors, GLP-1 Agonists andExpanding Insulin Segment to Drive Growth Summary GBI Research, the leading business intelligence provider, has released its latest research DiabetesTherapeutics Market in India to 2018 Rapid Uptake of DPP-IV Inhibitors, GLP-1 Agonists and ExpandingInsulin Segment to Drive Growth, which provides insights into the India anti-diabetes market until 2018. Thereport is built using data and information sourced from proprietary databases, primary and secondary researchand in-house analysis by GBI Researchs team of industry experts. Insights into the diabetes epidemiology,cost of therapy, research and development pipeline and the promising molecules which are anticipated to belaunched by 2018 are discussed in the report. The report provides an in-depth analysis type 1 and type 2diabetes. The report provides an in-depth analysis on oral anti-diabetics agents, insulin products and driversand barriers that could significantly impact the overall anti-diabetes market during the forecast period.Additionally, it explores the competitive landscape, including benchmarking the top companies in the marketand the key issues and trends that are likely to have an impact on the Indian diabetes market during theforecast period. Finally, a key trend analysis for mergers and acquisitions and licensing agreements involvingdiabetes therapies is also discussed in the report. GBI Researchs analysis revealed that the overall anti-diabetes market in India was worth $680.3m in 2011and is projected to grow at a CAGR of 11.3% between 2011 and 2018 to reach $1,446m in 2018. High andgrowing diabetes population in the country, rising obese and geriatric population, and rapid market adoptionof drugs from the classes such as Dipeptidyl Peptidase 4 (DPP-4) inhibitors, Glucagon-Like Peptide (GLP)-1,Sodium-Glucose Transport Proteins (SGLT-1) and others would drive the anti-diabetes market in the forecastperiod. The R&D product pipeline for DM, dominated by OAD agents, consists of around 200 molecules atvarious stages of clinical development. Paradoxically, type 2 diabetes therapeutics market, crowded with manygenerics and branded generics drug products, is being seen as a significant growth opportunity for new patentprotected products owing to high prevalence, progressive nature of the disease and considerably high unmetneeds. Of overall R&D pipeline molecules, more than 90% are being studied for the treatment of type 2 DM. Many multinational companies, such as Novartis, Eli Lilly, are engaged in setting up strategic marketing anddistribution agreements with domestic players to improve their patient base and so the market share. Growingat a double digit year on year growth rate, the Indian anti-diabetics market is very promising and offerslucrative opportunities to both domestic as well as foreign pharmaceutical players. Scope Data and analysis on the Indian diabetes therapeutics market Annualized market data for the diabetestherapeutics market from 2004 to 2011, with forecasts to 2018 for type 1 and type 2 diabetes. Epidemiologicaldata on type 1 and type 2 diabetes along with market size, annual cost of therapy, unmet needs and economicburden of diabetes. Key drivers and restraints that have had a significant impact on the market. Major trendsand issues which are likely to have a significant impact on overall diabetes therapeutics market in IndiaDiabetes Therapeutics Market in India to 2018 - Rapid Uptake of DPP-IV Inhibitors, GLP-1 Agonists and Expanding Insulin Segment to Dri
  • 2. Competitive landscape of the diabetes therapeutics market including top companies benchmarking. The keycompanies studied in this report are Novo Nordisk, Sanofi, Novartis, Eli Lilly, Merck, Abbott, USV, SunPharma, Biocon and Wockhardt. Key M&A activities and licensing agreements, major deals that took placein last four years in Indian diabetes therapeutics market. Reasons to buy Align their product portfolio to the markets with high growth potential. Build effective strategies to launchtheir pipeline products by identifying potential geographies. Exploit in-licensing and out-licensingopportunities by identifying products that might fill their portfolio gaps. Develop key strategic initiatives bystudying the key strategies of top competitors. Devise a more tailored country strategy through theunderstanding of key drivers and barriers and market potential. Develop market-entry and market expansionstrategies by identifying the geographic markets poised for strong growth. Reinforce R&D pipelines byidentifying new target mechanisms which can produce first-in-class molecules which are safer and moreefficacious.table Of Contents1 Table Of Contents1.1 List Of Tables1.2 List Of Figures2 Diabetes Therapeutics Market In India To 2018 - Overview2.1 Diabetes Mellitus - A Global Overview3 Diabetes Therapeutics Market In India - Introduction3.1 Type 1 Diabetes Mellitus3.1.1 People At Risk3.1.2 Risk Factors For Type 1 Diabetes3.1.3 Symptoms3.2 Type 2 Diabetes Mellitus3.2.1 People At Risk3.2.2 Risk Factors For Type 2 Diabetes3.2.3 Symptoms3.3 Gestational Diabetes Mellitus3.3.1 Risk Factors For Gestational Diabetes Mellitus3.4 Diagnosis Of Diabetes Mellitus3.5 Diabetes Treatment Guidelines - India3.5.1 Introduction3.5.2 Prevention Of Diabetes3.5.3 Diabetes TreatmentDiabetes Therapeutics Market in India to 2018 - Rapid Uptake of DPP-IV Inhibitors, GLP-1 Agonists and Expanding Insulin Segment to Dri
  • 3. 3.6 Diabetes Mellitus Complications4 Diabetes Therapeutics Market In India To 2018 - Major Drug Classes4.1 Sulfonylureas4.1.1 Introduction4.1.2 Mechanism Of Action4.1.3 Major Drugs4.2 Thiazolidinediones4.2.1 Introduction4.2.2 Mechanism Of Action4.2.3 Example4.3 Biguanides4.3.1 Introduction4.3.2 Mechanism Of Action4.3.3 Drug Products4.4 Meglitinides4.4.1 Introduction4.4.2 Mechanism Of Action4.4.3 Major Drugs4.5 Alpha-glucosidase Inhibitors4.5.1 Introduction4.5.2 Mechanism Of Action4.5.3 Major Drugs4.6 Glucagon-like Peptide Analogs And Agonists4.6.1 Description4.6.2 Mechanism Of Action4.6.3 Major Drugs4.7 Dipeptidyl Peptidase-4 Inhibitors4.7.1 Description4.7.2 Mechanism Of Action4.7.3 Major Drugs4.8 Glucagon-like Peptide-1 Analogs Vs. Dipeptidyl Peptidase-4 Inhibitors4.9 Insulin Preparations4.9.1 Introduction4.9.2 Types Of Insulin5 Diabetes Therapeutics Market In India To 2018 - Epidemiology5.1 Introduction5.2 Diabetes Population In India5.3 Diagnosed Population5.4 Treated PopulationDiabetes Therapeutics Market in India to 2018 - Rapid Uptake of DPP-IV Inhibitors, GLP-1 Agonists and Expanding Insulin Segment to Dri
  • 4. 6 Diabetes Therapeutics Market In India To 2018 - Revenue Forecasts6.1 Introduction6.1.1 Oral Anti-diabetics Market6.1.2 Insulin Market6.2 Annual Cost Of Therapy7 Diabetes Therapeutics Market In India To 2018 - Economic Burden Of Diabetes In India7.1 Economic Burden Of Diabetes In India7.1.1 Introduction7.1.2 Healthcare Expenditure On Diabetes In India7.2 Collaborative Efforts Necessary To Address The Rising Burden Of Diabetes8 Diabetes Therapeutics Market In India To 2018 - Drivers And Barriers8.1 Market Drivers8.1.1 Aging Population, Sedentary Lifestyle And Unhealthy Diet Is Driving The Diabetic Population In India8.1.2 Promising Molecules Offering Improved Clinical Outcomes Could Increase Patient Base On Therapy8.1.3 Untapped Areas Offer Promising Opportunities To Pharmaceutical Companies8.2 Market Barriers8.2.1 Low Diagnosis And Prescription Rate8.2.2 Highly Competitive Market Driven By Generics And Branded Generics Increases Pricing Pressure8.2.3 High Out-of-pocket And Low Healthcare Expenditure On Diabetes9 Diabetes Therapeutics Market In India To 2018 - Unmet Needs9.1 Introduction9.2 High Cost Of Therapy And Drug Safety Issues Affect Patient Compliance9.3 Unmet Need Creates Opportunities For Pharmaceutical Companies10 Diabetes Therapeutics Market In India To 2018 - Product Pipeline Analysis10.1 Profiles Of Promising Molecules In R&d Development10.1.1 In-105 (oral Insulin)10.1.2 Nn9068/ideglira/degludec +/- Liraglutide10.1.3 Dapagliflozin10.1.4 Canagliflozin/ta-728410.1.5 Lixisenatide10.1.6 AlogliptinDiabetes Therapeutics Market in India to 2018 - Rapid Uptake of DPP-IV Inhibitors, GLP-1 Agonists and Expanding Insulin Segment to Dri
  • 5. 11 Diabetes Therapeutics Market In India To 2018 - Case Studies11.1 Avandia Fallout Impact11.1.1 Introduction11.1.2 Cardiovascular Safety Issues11.1.3 Impact On Glaxosmithkline11.1.4 Impact On Drug Approvals11.2 Januvia From Merck An Example That Patented Products Can Succeed In India11.2.1 Introduction11.2.2 Improved Pharmacological Effect Of Dpp-4 Inhibitors Helped Rapid Adoption11.2.3 Januvia And Janumet A New Growth Engine For Merck11.2.4 Robust Approach Needed To Market A New Drug Product In India11.2.5 Excellent Commercialization Strategy11.2.6 Conclusion12 Diabetes Therapeutics Market In India To 2018 - Major Trends And Issues12.1 Biguanides Class Is Dominated By Generics12.2 Evolving Oral Hypoglycemic Agents Resulting In Smaller Market Share Sulfonylureas12.3 Increasing Competition In Dipeptidyl Peptidase-4 Inhibitor Class12.3.1 Dpp-4 Inhibitors Likely To Face Potential Competition From Glp-1 Agonists12.4 Thiazolidinedione Class To Face Impact Of Avandia Fallout12.5 Glp-1 Agonists Must Demonstrate Better Safety And Efficacy Profiles To Compete With Other OralHypoglycemic Class12.6 Fierce Competition In The Insulin Market Is Likely To Increase12.7 Is Oral Insulin The Next Big Thing In The Insulin Market?12.7.1 Introduction12.7.2 Oral Insulin Not For All12.7.3 Challenges To Overcome12.7.4 Would It Lead To Market Cannibalization?12.8 India Diabetes Market: Setting Up For The Biosimilars?12.8.1 Introduction12.8.2 Insulin Biosimilar Market12.8.3 Sanofi’s Lantus A Lucrative Target12.8.4 Need For Dose Adjustments Would Discourage Uptake Of Biosimilars12.8.5 Price Discounts Alone Would Be Insufficient12.8.6 Strong Brand Promotion Would Be Necessary For Insulin Biosimilars12.8.7 Collaborations And Licensing Agreements Are Key12.8.8 Conclusion12.9 Sodium Glucose Co-transporter2 Inhibitors: A New Class To Hit The Market?12.10 Glucokinase Activators12.11 Stem Cell Therapies: The Next Prospective Therapy For Diabetes?12.11.1 Introduction12.11.2 What Are Stem Cells?Diabetes Therapeutics Market in India to 2018 - Rapid Uptake of DPP-IV Inhibitors, GLP-1 Agonists and Expanding Insulin Segment to Dri
  • 6. 12.11.3 Stem Cell Therapies And Diabetes12.11.4 Conclusion12.12 Price Discounts A Decisive Factor In The Increasingly Competitive Anti-diabetes Market12.13 Favorable Government Polices To Promote Generics12.14 Strategic Consolidation To Increase Growth Prospects12.14.1 Introduction12.14.2 Shift Of Focus Towards Rural And Class Ii-iv Towns13 Diabetes Therapeutics Market In India To 2018 - Competitive Landscape13.1 Novartis India Limited (novartis India)13.2 Novo Nordisk India Private Limited (novo)13.3 Eli Lilly And Company (india) Pvt. Ltd. (eli Lilly)13.4 Merck Sharp Dohme India13.5 Abbott India Limited (abbott India)13.6 Sun Pharmaceutical Industries Limited (sun Pharma)13.7 Usv Limited13.8 Wockhardt Limited (wockhardt)13.9 Sanofi India Limited13.10 Biocon Limited (biocon)14 Diabetes Therapeutics Market In India To 2018 - Strategic Consolidations14.1 Introduction14.2 Diabetology Entered Into Licensing Agreement With Usv For Capsulin On July 31, 201214.3 Merck Sharp & Dohme Entered Into Co-marketing Agreement With Sun Pharma On April 25, 201114.4 Eli Lilly And Company (india) Entered Into Co-promotion Agreement With Lupin On July 29, 201114.5 Sheffield Bio-science Entered Into Collaboration With Wockhardt On February 21, 201114.6 Eli Lilly Entered Into Co-promotion Agreement With Boehringer Ingelheim For Humalog AndLinagliptin On October 3, 201114.7 Novartis India Entered Into Co-marketing Agreement With Usv On December 31, 200814.8 Pfizer-biocon Deal Called Off In March 201214.8.1 Impact Analysis15 Diabetes Therapeutics Market In India To 2018 - Appendix15.1 Market Definitions15.2 Abbreviations15.3 Bibliography15.4 Research Methodology15.4.1 Coverage15.4.2 Secondary Research15.4.3 Primary ResearchDiabetes Therapeutics Market in India to 2018 - Rapid Uptake of DPP-IV Inhibitors, GLP-1 Agonists and Expanding Insulin Segment to Dri
  • 7. 15.5 Therapeutic Landscape15.5.1 Market15.6 Geographical Landscape15.7 Pipeline Analysis15.8 Competitive Landscape15.8.1 Expert Panel Validation15.9 Contact Us15.10 DisclaimerAbout Us:Transparency Market Research is a market intelligence company providing global business informationreports and services. Our exclusive blend of quantitative forecasting and trends analysis providesforward-looking insight for thousands of decision makers. We are privileged with highly experienced team ofAnalysts, Researchers and Consultants, who use proprietary data sources and various tools and techniques togather, and analyze information. Our business offerings represent the latest and the most reliable informationindispensable for businesses to sustain a competitive edge.Contact:ResearchMoz90 State Street,Suite 700,Albany NY - 12207United StatesTel: +1-518-618-1030USA - Canada Toll Free 866-997-4948Email: sales@researchmoz.usBlog: http://researchmoz.blogspot.com/Website: http://www.researchmoz.us/Diabetes Therapeutics Market in India to 2018 - Rapid Uptake of DPP-IV Inhibitors, GLP-1 Agonists and Expanding Insulin Segment to Dri